Genome editing of human embryos could become a fundamental treatment approach for genetic diseases; however, a few technical and ethical issues need to be resolved before its application in clinical settings. Presently, the Japanese government has issued a statement prohibiting human germline editing and emphasizing the need for discussions that include a wide range of perspectives. However, current discussions tend to exclude the general public. Therefore, we conducted a survey of 10,881 general adults and 1044 patients in Japan who indicated that their disease conditions are related to their genetic makeup, and clarified their attitude toward this technology. The results clearly indicated that the Japanese people generally accepted the use of genome editing for disease-related genes, but many were concerned about the risks. In addition, many Japanese people did not understand the technology well. To improve awareness and understanding about genome editing, it is important that scientists and science communicators create opportunities for the public to participate in relevant discussions without harming vulnerable participants. It is also important to continuously track changes in the acceptance of genome editing by the public.
Genome editing involves insertion, deletion, or modification of DNA with increased specificity and efficiency at a specific site in the genome . This technology can be applied to research, agriculture, and medical care. Following the first application of the CRISPR/Cas9 system in abnormally fertilized embryos by Chinese researchers , the United States National Academy of Sciences hosted an international summit and promptly issued a statement regarding serious concerns related to germline genome editing, including risks of inaccurate editing and ethical issues . In Japan, the Expert Panel on Bioethics of the Council for Science, Technology, and Innovation issued a tentative statement on the use of genome editing in human embryos, raising similar concerns including the difficulty of predicting possible harmful effects of genetic changes under various circumstances experienced by the human population and the possibility that permanent enhancements in genetic subsets of the population could exacerbate social inequities or be used coercively . Furthermore, presently, four Japanese academic societies have requested that the government prohibit human germline genome editing . Apart from the interim moratorium on clinical application, these statements emphasize the need for discussions that include various perspectives, i.e., those of patients, their families, and the public.
Previous studies have shown that the public is generally supportive of germline genome editing to cure life-threatening diseases, but not for genetic enhancement [5, 6]. Another survey revealed that the people in the United States want to engage in discussions on genome editing . However, these surveys did not investigate stakeholders separately. In particular, patients with genetic conditions are important stakeholders because they or their offspring are likely to be clinical trial participants and beneficiaries of germline editing  or, in the worst case, to be candidate eugenic targets if this technology is misused. Thus, we conducted an online survey in Japan to clarify the attitude of the public and patients diagnosed with or at a risk of developing genetic conditions toward genome editing.
Cross-sectional and anonymous online surveys were conducted by administering the same questionnaire to 44,360 general adults (GAs) in the general Japanese population aged 20–69 years and 6522 Japanese patients aged 20–79 years. The study duration ranged from February to March 2017. GAs were extracted from the survey panel of INTAGE Inc., based on sex, age, and residential area according to the national census data. Japanese patients who visited a hospital or were hospitalized for cancer or cardiovascular, cerebrovascular, or psychiatric diseases within the last year were enrolled. After reading the text explaining the characteristics of genome editing, which included differences between genome editing and genetic recombination, and effects of genome editing of fertilized embryos on the next generation, respondents were questioned about the awareness, level of understanding, criteria, and risks of germline genome editing.
The GAs group included 10,881 respondents (response rate: 24.5%) and the Japanese patient group included 4195 respondents (64.3%). We extracted respondents who indicated that their disease conditions were related to their “genetic makeup” (Pts, n = 1044) from the Japanese patient group and compared their attitudes with those of the GAs (Table 1).
Regarding the perception of the term “genome editing,” 6.6% of GAs and 11.5% of Pts responded, “understand what it means,” and 67.2% of GAs and 58.0% of Pts responded that they “have never heard of genome editing” (Table 1). Among respondents who indicated, “I understand what it means,” 24.2% of GAs and 31.0% of Pts incorrectly answered a true or false question on the basic nature of the CRISPR/Cas9 system. Pts were more aware of genome editing than GAs, which might be because Pts were more interested in this technology. This result possibly indicates that awareness in Japan is lower than that in the USA (“a lot” 9%, “not at all” 42%) .
Furthermore, we investigated differences in the awareness and acceptance rate and perceived risks of human germline genome editing. The survey respondents were age-matched by excluding those aged ≥70 years from the Pt group. Acceptance rates for “may be performed for disease that shorten a baby’s life” were related to awareness in the Pt and GA groups (P < 0.01), and residual analysis indicated that the group that answered “understanding what it means” had significantly higher acceptance than the other groups (Fig. 1). In addition, acceptance rates of “may be performed for disease that require long term care” were related to awareness in the Pt and GA groups (P < 0.01), and residual analysis indicated that the group that answered “understanding what it means” had significantly higher acceptance than the other groups (Fig. 1). Thus, the high-awareness group had a possibly high acceptance rate for genome editing in this survey. However, the Pt and GA groups showed high concerns for germline genome editing regardless of awareness (Fig. 2). In the Pt group, respondents who indicated “understanding what it means” had concerns about humans changing the genes of other humans (P < 0.01). This result indicated that Pts anticipate the application of genome editing, but they have ambivalent feelings, similar to GAs.
This survey had a potential recruitment bias because it was conducted online and the health conditions of Pts were self-reported. Moreover, it is also thought that detailed investigation on awareness is necessary. However, the results provided insights into the attitude of the public toward the use of genome editing in Japan. Despite low awareness and inadequate understanding about genome editing before responding to our survey, our respondents were accepting of its use in targeting of disease-related genes, albeit with substantial concerns about risks.
This survey also showed that Pts anticipate the application of genome editing, although with substantial concerns about risks. The desire of Pts to avoid transferring their pathogenic gene mutations to future generations may be a reason for these differences. Therefore, we think that increasing awareness of genome editing is necessary, and science communicators and scientists should involve such vulnerable stakeholders in discussion on the topic, while considering and referencing ethical and other associated socio-scientific issues .
As inclusivity is an important factor in responsible science , appropriate forums should be established where all interested stakeholders can participate. Open and fact-based discussions will allow participants to have more concrete ideas. However, science communicators and scientists must direct attention to the whole process of discussions and be careful not to harm or stigmatize vulnerable participants. Although preimplantation genetic diagnosis (PGD) was not investigated here, we believe that a conscious survey, including that for the use of PGD, should be conducted.
Soon, awareness of germline genome editing is predicted to increase owing to media exposure. Therefore, it is important to continuously conduct similar investigations to track changes in the acceptance of genome editing and perception of its risks in the public.
Baltimore D, Baylis F, Berg P, Daley GQ, Doudna JA, Lander ES. et al. On human gene editing: International summit statement. Washington DC: National Academy of Sciences; 2015.
Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell. 2015;6:363–72.
The Expert Panel on Bioethics of the Council for Science, Technology and Innovation. On research using genome editing technology for human embryos. Interim summary. 2016.
Japan Society of Gene and Cell Therapy, Japan Society of Human Genetics, Japan Society of Obstetrics and Gynecology, and Japan Society for Reproductive Medicine. Recommendation on human genome editing. 2016.
McCaughey T, Sanfilippo PG, Gooden GE, Budden DM, Fan L, Fenwick E, et al. A global social media survey of attitudes to human genome editing. Cell Stem Cell. 2016;18:569–72.
Funk C, Kennedy B & Podrebarac Sciupac, E. U.S. public wary of biomedical technologies to ‘enhance’ human abilities. Pew Res Center. 2016;1–131.
Scheufele DA, Xenos MA, Howell EL, Rose KM, Brossard D, Hardy BW. U.S. attitudes on human genome editing. Science. 2017;357:553–4.
National Academy of Sciences, Engineering, and Medicine. Human genome editing: science, ethics, and governance. Washington, DC: The National Academies Press; 2017.
Sadler TD, Zeidler DL. Patterns of informal reasoning in the context of socioscientific decision making. J Res Sci Teach. 2005;42:112–38.
Stilgoe J, Owen R, Macnaghten P. Developing a framework for responsible innovation. Res Pol. 2013;42:1568–80.
We express our gratitude to all the survey participants and The National Museum of Emerging Science and Innovation. This research was supported by the Health Labor Sciences Special Research Grant, and by AMED under Grant Number JP16cm0106001 and JP16bm0504010.
Conflict of interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Uchiyama, M., Nagai, A. & Muto, K. Survey on the perception of germline genome editing among the general public in Japan. J Hum Genet 63, 745–748 (2018). https://doi.org/10.1038/s10038-018-0430-2
Public attitudes in the clinical application of genome editing on human embryos in Japan: a cross-sectional survey across multiple stakeholders
Journal of Human Genetics (2022)
Agriculture and Human Values (2022)
BMC Medical Ethics (2021)
Genetics experience impacts attitudes towards germline gene editing: a survey of over 1500 members of the public
Journal of Human Genetics (2020)
Attitudes of clinical geneticists and certified genetic counselors to genome editing and its clinical applications: A nation-wide questionnaire survey in Japan
Journal of Human Genetics (2019)